TSE:4506Pharmaceuticals
A Look At Sumitomo Pharma’s Valuation As AMCHEPRY Wins Conditional Approval And Guidance Rises
Sumitomo Pharma (TSE:4506) just secured conditional Japanese approval for AMCHEPRY, an iPS cell based Parkinson’s therapy, alongside raising its fiscal 2026 earnings guidance and considering a new share issuance, putting the stock firmly on investors’ radar.
See our latest analysis for Sumitomo Pharma.
The conditional AMCHEPRY approval and raised fiscal 2026 guidance arrive after a volatile period, with a 1 year total shareholder return of 174.36% contrasting with a weaker recent 7 day share...